Ali AlHusry - Hikma Pharmaceuticals Non-Executive Director
HIK Stock | EUR 151.00 2.00 1.34% |
Director
Mr. Ali K. AlHusry is NonExecutive Director of Hikma Pharmaceuticals Plc. Ali held various management and leadership roles within Hikma before stepping into an advisory role in 1995, when he founded Capital Bank of Jordan, focusing on commercial and investment banking. Ali served as Chief Executive of the Bank until 2007. Mechanical Engineering degree from the University of Southern California, MBA from INSEAD. since 2005.
Age | 59 |
Tenure | 19 years |
Professional Marks | MBA |
Web | https://www.hikari.co.jp |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0231 % which means that it generated a profit of $0.0231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1885 %, meaning that it generated $0.1885 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 6 records | DIRECTOR Age | ||
Christian Illek | T Mobile | 54 | |
Srinivasan Gopalan | T Mobile | 48 | |
Ronald Fisher | T Mobile | 71 | |
Thorsten Langheim | T Mobile | 53 | |
Raphael Kubler | T Mobile | 56 | |
Raul Claure | T Mobile | 48 |
Management Performance
Return On Equity | 0.19 | |||
Return On Asset | 0.0231 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Fadi Nassar, Corporate Vice President - Active Pharmaceutical Ingredients | ||
Bassam Kanaan, Chief Strategy & Corporate Development Officer | ||
Khalid Nabilsi, CFO | ||
Hussein Arkhagha, General Counsel | ||
Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
Pamela Kirby, Non-Executive Independent Director | ||
John Castellani, Non-Executive Independent Director | ||
Brian Hoffman, President and Chief Executive of - Generics Division | ||
Ali AlHusry, Non-Executive Director | ||
Jochen Gann, Non-Executive Director | ||
Hideaki Wada, CEO Pres | ||
Koh Gidoh, GM MD | ||
Peter Speirs, Company Secretary | ||
Patrick Butler, Non-Executive Independent Director | ||
Said Darwazah, Chairman of the Board, Chief Executive | ||
Michael Raya, President and CEO, USA | ||
Ronald Goode, Non-Executive Independent Director | ||
Bryan Hotston, CIO | ||
Sigurdur Olafsson, CEO | ||
Yasumitsu Shigeta, Chairman Founder | ||
Breffni Byrne, Non-Executive Independent Director | ||
Nina Henderson, Non-Executive Independent Director | ||
Cynthia Schwalm, Independent Non-Executive Director | ||
Ragheb AlShakhshir, Corporate Vice President - Research & Development | ||
Michael Ashton, Non-Executive Independent Director | ||
Majda Labadi, Corporate Vice President - Human Resources | ||
Ibrahim Jalal, Senior Corporate Vice President - Technical Affairs | ||
Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
Robert Pickering, Senior Non-Executive Independent Director | ||
Mazen Darwazah, Executive Vice Chairman of the Board; President and CEO of MENA and Emerging Markets | ||
Masato Takahashi, Director Director |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.19 | |||
Return On Asset | 0.0231 | |||
Profit Margin | 0.15 % | |||
Operating Margin | 0.09 % | |||
Current Valuation | 7.67 B | |||
Shares Outstanding | 44.31 M | |||
Shares Owned By Insiders | 57.06 % | |||
Shares Owned By Institutions | 14.55 % | |||
Price To Earning | 23.96 X | |||
Price To Book | 1.55 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hikma Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hikma Pharmaceuticals' short interest history, or implied volatility extrapolated from Hikma Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Hikma Stock analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |